ANDA 89624, held by Organon USA. Edrophonium Chloride.
As of Nov 21, 2026, ANDA 89624 (Reversol), held by Organon USA, was first approved by FDA on May 13, 1988, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 13, 1988 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Reversol10MG/ML · injectable;injection | Edrophonium Chloride | Discontinued |
| Jun 9, 1999 | Supplement 8Manufacturing | Approved | None posted |
| Mar 27, 1996 | Supplement 6Manufacturing | Approved | None posted |
| Jan 23, 1996 | Supplement 7Manufacturing | Approved | None posted |
| Mar 7, 1994 | Supplement 5Manufacturing | Approved | None posted |
| Nov 4, 1993 | Supplement 4Labeling | Approved | None posted |
| May 8, 1992 | Supplement 3Manufacturing | Approved | None posted |
| Feb 6, 1992 | Supplement 2Manufacturing | Approved | None posted |
| May 13, 1988 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters